Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) — the incoming chair and ranking member of the Finance Committee, respectively — plan to introduce a bill cracking down on the kind of tactics Mylan used to pay lower Medicaid rebates for EpiPens.
Why it matters: This is a strong signal that there's room for the committee to work together on drug pricing issues next year.
Details: EpiPen was misclassified as a generic drug within the Medicaid drug rebate program, which resulted in Mylan paying less in rebates and causing taxpayers to overpay as much as $1.27 billion over 10 years, according to one government estimate.
- The Grassley-Wyden bill gives HHS the explicit authority to reclassify drugs, recover incorrect rebate payments and fine companies that knowingly misclassify drugs.
- It also requires HHS to submit reports to Congress on how its new authority has been used.
